Post-approval studies (Phase 4)Study completedNCT00980018
What this trial is testing
An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment
Who this might be right for
Chronic Myelogenous Leukemia
Novartis Pharmaceuticals 52